About the Journal

Editorial Board


Ece D. Uzun, MS, PhD

Director of Clinical Bioinformatics, Lifespan Academic Medical Center 
Associate Director, Center for Clinical Cancer Informatics and Data Science (CCIDS)
Assistant Professor of Pathology and Laboratory Medicine, Brown University, Alpert Medical School
Research Focus

Dr. Uzun has a strong analytical background and extensive experience in bioinformatics and biotechnology. As the Director of Clinical Bioinformatics at Lifespan, Dr. Uzun oversees the bioinformatic analysis of Next Generation Sequencing (NGS) based clinical assays.  In addition to her clinical work, she performs research in the areas of bioinformatics tool and algorithm development, network biology, machine learning based predictive models with a specific focus on cancer as well as neurodevelopmental disorders. Her research team is a group of individuals from multiple disciplines and diverse backgrounds. Dr. Uzun has served as an Associate Editor in two other journals before she joined JMIR Bioinformatics and Biotechnology ast the new Editor-in-Chief. She will focus on supporting the editorial board to improve the visibility of JBB and excel the quality of the publications.


Dr. Uzun is currently the Director of Clinical Bioinformatics and Associate Director of Clinical Cancer Informatics and Data Science (CCIDS) at Lifespan and an Assistant Professor of Pathology and Laboratory Medicine at Brown University Alpert Medical School.  She has a B.S in Chemical Engineering and M.Sc in Biological Sciences and Bioengineering. She completed her PhD in Chemical Engineering at Northeastern University in 2010 and focused  on mathematical modeling of drug delivery systems. During her postdoctoral training, she worked on computational genetics and bioinformatics with a focus on neurodevelopmental disorders. 

Editorial Board Members (Section Editors)

Alper Uzun, MS, PhD

Research Focus

Dr. Alper Uzun uses genomics and bioinformatics to study the genetic basis of complex diseases, specifically cancer. He is developing new computational approaches in network biology, variant data analysis, and visualization in order to gain a better understanding of complex diseases.


Dr. Alper Uzun is an Associate Professor of Pathology and Laboratory Medicine, with a secondary appointment in Pediatrics and Director of Cancer Bioinformatics at Legorreta Cancer Center at Brown University. Dr. Uzun trained formally as a computational biologist and bioinformatician. He has extensive knowledge and experience in clinical biochemistry, bioinformatics, human genetics, and genomics from his training. His research group works on translational
bioinformatics, focusing on the genetics of complex diseases especially focused on cancer from a network biology perspective.

Sean M. Hacking, MB, BCh, BAO

Research Focus

Dr. Sean M. Hacking is a pathologist with interests in machine intelligence, distributed ledger technology, genomics, and translational oncology. He has developed novel approaches to whole slide images in cancer and is working to foster novel mutli-omic techniques to better understand the tumor ecosystem.


Sean earned his MB,BCh,BAO from the National University of Ireland, Galway and completed his residency training in Anatomic and Clinical Pathology at the Donald and Barbara Zucker School of Medicine in New York and a Gastrointestinal and Surgical Pathology fellowship at the Rhode Island Hospital and Brown University. He has published over fifty papers on the tumoral microenvironment, cancer prognostication and machine intelligence. His work on stroma has better defined the metastatic/mesenchymal capacity of numerous cancer subtypes. He is actively working to create new digital cancer ecosystems to deliver more precision-based care opportunities. Sean most recently served as a clinical investigator at The Princess Margaret Cancer Centre, University of Toronto and has ML licensure in the states of New York, Pennsylvania, and Mississippi. Sean founded Odyssey-HCS with the hope of creating a next-generation healthcare ecosystem for a truly empowered future of precision medicine.